LMWHs is a common and unpredictable problem. We present two cases of patients who developed DHR to nadroparin and enoxaparin, respectively. The third case presents a patient who developed IHR to nadroparin. Skin tests confirmed the hypersensitivity in all cases. In the cases of DHR, a skin test negative LMWH was identified and was tolerated in a challenge test. In the IHR case, crossreactivity to all tested LMWHs was established. We hypothesize that the degree of cross-reactivity might depend on the type of hypersensitivity reaction with immediate reactions linked to more extensive cross-reactivity than delayed reactions. This is important to consider since, at least in some cases, a safe alternative LMWH can be identified.
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Manuscript text Introduction
Low molecular weight heparins (LMWH) are used daily for a variety of indications. Although considered safe medications, hypersensitivity reaction can occur. The most common type of hypersensitivity reactions to LMWHs are delayed-type hypersensitivity reactions (DHR) which are reported in up to 10% of patients (Schindewolf et al. 2009; Schindewolf et al. 2013) . Clinical manifestations of DHR include erythematous plaques and maculopapular exanthemas at the injection site. Immediate-type hypersensitivity reactions (IHR) to LMWHs are extremely rare and are limited to case reports (Gonzalez-Delgado and Fernandez 2016; MacLaughlin et al. 2002; Anders and Trautmann 2013; Leguísamo et al. 2015) . Clinical manifestations of IHR include urticaria, hypotension, angioedema, pruritus and anaphylaxis.
Skin tests including prick and intradermal test followed by a subcutaneous challenge test have been performed to establish the diagnosis of hypersensitivity to LMWHs and are generally recommended (Bircher et al. 2006; Brockow et al. 2013) . Testing is contraindicated in cases of heparin induced thrombocytopenia (HIT). The problem of cross-reactivity among different LMWHs has been widely recognised and is reported in the literature in up to 89.7% of patients (Weberschock et al. 2011; Grassegger et al. 2001 ). Identification of a subset of patients who can tolerate an alternative LMWH after a hypersensitivity reaction to a single LMWH would be of great clinical value. However, literature on such successful identifications is limited.
Methods
Skin test procedures at our Department are based on European Network for Drug Allergy (ENDA) publications (Brockow et al. 2002; Brockow et al. 2013) . Prick tests are performed using undiluted commercially available LMWH preparations. Histamine is used as a positive, and 0.9% saline as a negative control. Readings are done after 10 minutes for histamine and after 20 minutes for tested LMWHs. Following negative results, intradermal tests are performed with LMWHs diluted to 1:10. Readings are done after 20 minutes (immediate reading) and on days 2, 3 and 7 (delayed readings). Immediate readings are considered positive if the size of the initial wheal increases by at least 3 mm in diameter after 20 minutes. Delayed readings are considered positive if the presence of infiltrated erythema is observed. After the completion of skin tests, a skin-test negative preparation is chosen for the subcutaneous challenge test. Undiluted LMWH is injected subcutaneously in the lower abdominal area with readings after 20 minute (immediate) and on days 2, 3 and 7 (delayed readings).
Results (Case reports)
Case No 1 presents a 40-year old female patient with a history of previous exposure to LMWH who developed generalised erythematous itchy plaques in 2015 after the administration of nadroparin prophylactically following knee surgery. The reaction developed after 2 days of nadroparin administration, but the exact time elapsed from the last nadroparin injection to the development of the cutaneous reaction could not be established. She was evaluated at our Department in June 2016. After obtaining a written consent, skin tests to dalteparin, nadroparin and enoxaparin were performed. Following negative prick tests to all tested heparins, intradermal tests (ID) were D r a f t performed and immediate readings were positive to nadroparin and dalteparin. Since ID tests to enoxaparin were negative, a subcutaneous challenge test with enoxaparin (1000 IU, 0.1ml) with immediate and delayed readings on days 0, 2, 3 and 7 was performed. All delayed readings were negative. Enoxaparin was well tolerated and provoked neither an immediate nor a delayed skin reaction. The patient was provided with written advice to avoid nadroparin and dalteparin while enoxaparin can be used as indicated.
Case No 2 presents a 43-year old female patient who developed a skin reaction (without additional details provided) after 7 days of prophylactic treatment with enoxaparin due to a history of several miscarriages in June 2015. The exact time elapsed from the seventh injection of enoxaparin to the onset of the skin reaction could not be established. After the onset of the reaction the patient was switched to nadroparin. Nadroparin was administered for 2 days but was discontinued due to the persistence of the skin reaction. Further use of LMWHs was not deemed necessary since the patient experienced another miscarriage while on LMWH therapy. She was evaluated at our Department in September 2015. After obtaining a written consent, skin tests to dalteparin, nadroparin and enoxaparin were performed. Following negative prick test, ID test were performed. Immediate readings were negative to enoxaparin and dalteparin and positive to nadroparin. In the delayed readings on days 2, 3 and 7, the sites of ID test to enoxaparin showed redness and itching and a delayed-type of hypersensitivity to enoxaparin was established. Delayed readings of ID test to nadroparin and dalteparin were negative. A subcutaneous challenge test with dalteparin (1250 IU, 0.1ml) was then performed with immediate and delayed readings. Dalteparin was well tolerated and provoked neither an immediate nor a delayed skin reaction. The patient was provided with written advice to avoid nadroparin and enoxaparin while dalteparin can be used as indicated.
Case No 3 presents a 35-year old female patient who developed a severe skin reaction (documented as such in the discharge letter from the local hospital) after the administration of nadroparin prophylactically for a breast fibroadenoma removal in September 2015. The patient recalls the development of generalised skin redness. The reaction occurred several minutes after the administration of the first dose of nadroparin, and her surgery was cancelled. Her past medical history was remarkable for chronic urticaria that was inactive at the time of the reaction. She was evaluated at our Department in October 2015. After obtaining a written consent, skin tests to dalteparin, nadroparin and enoxaparin were performed. Twenty minutes after prick tests were performed; the development of a few erythematous plaques was noted. Since the skin area around the prick tests was unaffected, it was decided to proceed with intradermal tests. The immediate reading was positive for nadroparin and negative for other tested heparins. However, in the following 2 hours the patient developed generalised urticaria that required treatment with oral antihistamines and corticosteroids. Urticaria subsided in the course of the following few days. The patient was re-evaluated at our Department 7 months after the initial testing. The same procedure for skin test was followed except that each heparin was tested on a separate day. Skin tests to both dalteparin and enoxaparin were positive in the immediate readings and produced generalised urticaria. A diagnosis of immediate-type hypersensitivity LMWHs was made and cross-reactivity to all tested LMWHs was confirmed. The patient was provided with written advice to avoid all LMWHs.
A summary of results is available in Table 1 .
The exact mechanism of hypersensitivity reactions to LMWHs is unknown. It has been proposed that each heparin carries an individual, drug-specific risk for inducing hypersensitivity reactions. Evidence in support of this proposal is limited (Brockow et al. 2002) . Cross-reactivity of different LMWHs is a well-known problem. However, it is impossible to predict the pattern of cross-reactivity among different LMWHs since the it does not seem to depend on the molecular weight of heparins (Weberschock et al. 2011 ). Due to a limited number of published reports with negative challenge tests (for DHR) and a very low prevalence of IHR, cross-reactivity to other LMWHs has not yet been explained (Canti et al. 2015; Bircher et al. 1995) .
We present two cases of DHR in which cross-reactivity studies have been performed, and tolerance of a skin test negative LMWH has been proven. In Case 1, cross-reactivity was established between nadroparin and dalteparin while enoxaparin was tolerated in a subcutaneous challenge test. In Case 2, cross-reactivity was established between enoxaparin and nadroparin while dalteparin was tolerated in a subcutaneous challenge test.
Our two cases are consistent with other published cases of DHR. Canti describes a case of crossreactivity between enoxaparin and nadroparin while dalteparin was tolerated in a subcutaneous challenge test which is identical to our Case 2 (Canti et al. 2015) . Colom describes 3 cases of DHR to LMWHs (Palacios Colom et al. 2008 ). The first case describes complete cross-reactivity among the tested LMWHs (nadroparin, dalteparin, enoxaparin and bemiparin). The second case describes crossreactivity between nadroparin and dalteparin, while skin tests remained negative to bemiparin and enoxaparin. However, tolerance to bemiparin and enoxaparin cannot be established since challenge tests have not been performed. The third case describes cross-reactivity between enoxaparin and dalteparin. Skin tests remained negative to nadroparin and bemiparin. However, challenge test was positive for bemiparin, while tolerance to nadroparin cannot be established since challenge test was not done. Grassegger describes 13 cases of DHR to different LMWHs (Grassegger et al. 2001 ).
Patients were tested subcutaneously to several LMWHs. Although details are not provided, the results of the study indicate that complete cross-reactivity to all tested heparins was established in 4 cases while no cross-reactivity among LMWHs was found in 7 cases. In the remaining 2 cases, crossreactivity was found between 2 LMWHs but at least one other test-negative LMWH could be identified.
An important advantage of our DHR cases is the performance of challenge tests. This has important clinical value, since a safe LMWH has been identified for future use. We could argue that the challenge dose should have been higher or that the true tolerance could only be established after a course of LMWH and a follow-up. Although that would certainly add strength to our cases, our report is done in a retrospective way and as such carries imperfections that do not underrate its overall scientific contribution. In cases 2 and 3, we were able to adhere to the optimal time period for performance of skin tests (between 3 weeks and 3 months after the reaction) (Brockow et al. 2002 ). An inadvertent variation occurred in the testing protocol for Case 1 compared to Cases 3 and 4. In Case 1, challenge test was done on the same day as the intradermal tests, and the delayed readings were performed parallel to ID and challenge tests. Since all ID and challenge test were negative, this protocol variation did not influence the validity of the final results. Table 2 . Anders describes a case of IHR to enoxaparin with cross-reactivity to nadroparin but negative skin tests to dalteparin (Anders and Trautmann 2013) . However, since only prick tests have been performed, a conclusion on tolerance of dalteparin cannot be made. Moreover, the authors do not state the time elapsed from the anaphylactic reaction to testing. This is an important missing information since the testing should be postponed until the resolution of clinical symptoms and clearance of the incriminated drug and of the antiallergic medications from the circulation (Brockow et al. 2002) . Caballero describes two cases of IHR to enoxaparin (Caballero and Fernandez-Benitez 2003) . However, for the purpose of this review only one case (with positive skin tests to culprit drug) is considered relevant. Although prick tests to enoxaparin and nadroparin were negative, immediate and delayed readings of intradermal tests to both LMWHs were positive. The authors found positive ID tests to calcium heparin and presented a novel in vitro diagnostic technique, the basophil activation test (BAT). Since only 2 LMWHs were tested in this case, a more detailed insight into the patterns of cross-reactivity could not be made.
Gonzalez describes a case of IHR to bemiparin and enoxaparin (González et al. 2014) . Skin tests were done for several LMWHs (enoxaparin, bemiparin, dalteparin, nadroparin, tinzaparin) UFH, fondaparinux and lepirudin. Intradermal tests were positive for all LMWHs and negative for all other tested drugs. Challenge tests confirmed tolerance of UFH, fondaparinux and lepirudin. Harr describes a case of IHR to dalteparin . Skin tests were positive for all tested LMWHs (dalteparin, nadroparin, enoxaparin) but were negative to UFH, danaparoid, lepirudin and fondaparinux. Challenge tests confirmed tolerance of UFH and fondaparinux. Time elapsed from the anaphylactic reaction to testing is not stated. Bekkenk describes a case of IHR to nadroparin that showed cross-reactivity to dalteparin but skin tests were negative to enoxaparin and tinzaparin. However, challenge with enoxaparin resulted in generalised urticaria, so the skin test was presumably falsely negative and the tolerance of tinzaparin could not be established since challenge test was not performed (Bekkenk and van Zuuren 2005) . Cesana describes two cases of IHR to dalteparin (Cesana et al. 2016) . For the purpose of this review only one case (with positive skin tests to culprit drug) is considered relevant. Skin tests were positive to dalteparin, nadroparin and enoxaparin and negative for UFH and fondaparinux. The tolerance of the latter two drugs was confirmed with a challenge test. Kavut describes a case of IHR to enoxaparin (Kavut and Koca 2012) . Skin tests were positive to enoxaparin but negative to other tested LMWHs (nadroparin, dalteparin, tinzaparin). However, challenge tests were positive for the 3 skin test negative LMWHs. The reason for the unexpected results of challenge tests might be in the fact that testing was done shortly after the reaction. If skin tests are performed within the next few days of the reaction, testing is considered unreliable and might be falsely negative due to histamin depletion (Brockow et al. 2002) .
Our Case 3 is consistent with other published cases of IHR to a LMWH. An advantage of our case is adherence to the recommendation about timing of skin tests. Moreover, our patient underwent the testing procedure twice with the same end result, which adds to the credibility of the results. Not including UFH and fondaparinux might be perceived as a shortcoming of our case. Although this would be of benefit, our patient subsequently underwent the fibroadenoma removal without anticoagulation and was unwilling to proceed with further testing.
D r a f t
Weberschock proposes that a differential degree of cross-reactivity might depend on the anticoagulant inducing the DHR (Weberschock et al. 2011) . We additionally propose that the degree of cross-reactivity might depend on the type of hypersensitivity reaction elicited. Although based on only eight cases altogether, we hypothesize that in the case of immediate hypersensitivity reactions to a LMWH, cross-reactivity to all available LMWHs should be assumed. On the other hand, in the case of delayed-type hypersensitivity reactions to a LMWH, a safe alternative LMWH can sometimes be identified and complete cross-reactivity seems less likely.
In the case of cross-reactivity to all LMWHs, several options exist. The patient could be switched to oral anticoagulants, fondaparinux or other anticoagulants might be used, and even intravenous administration of UFH might be tolerated. However, the administration of other parenteral anticoagulants should be discouraged without prior testing since broader cross-reactivity is possible.
Desensitization might be considered for patients with IHR to a LMWH and a complete crossreactivity to the drug class. Our literature search revealed three cases of successful desensitization with un-fractionated heparin in patients who experienced IHR to heparins (LMWHs in two cases and UFH in one case) (Kavut and Koca 2012; Altintaş et al. 2009; Parekh et al. 2005) . However, to the best of our knowledge there are no published cases of desensitization with LMWHs. The decision to proceed with desensitization is made if alternative medications are not available or are of inferior therapeutic efficacy. In our Case 3, additional testing to fondaparinux and UFH should be performed prior to possible desensitization.
Further studies are necessary in the field of cross-reactivity to LMWHs. The studies should optimally include patients with IHR in whom different available parenteral heparins are tested following the principles set out in the relevant literature. More published cases of IHR to a LMWH would allow us to identify a possible pattern of cross-reactivity and would enable us to test the hypothesis of different degree of cross-reactivity based on the type of reaction elicited.
Conclusion
In conclusion, a definite diagnosis of hypersensitivity to LMWHs should be established in order to guide further anticoagulant treatment. The diagnosis is based on history and skin tests, and tolerance is proven with a challenge test. We suggest that patients with DHRs to LMWHs be evaluated by means of skin tests to all available LMWHs and that the challenge tests are performed with a skin test negative LMWH. Different LMWHs show broad, but not complete cross-reactivity. The cross-reactivity is unpredictable, linked to the culprit LMWH and possibly to the type of initial reaction. At least in some cases, a safe alternative LMWH can be identified in patients who have experienced a DHR to a LMWH. 
